- Darzalex Faspro (Janssen)Expanded Indication
- For induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma.
- Shield™ blood test (Guardant Health)
- For colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
- Palforzia (Aimmune Therapeutics)Expanded Indication
- To include initiation of treatment, up-dosing and maintenance in individuals ages 1 through 3 years with a confirmed diagnosis of peanut allergy to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanuts.
- Erzofi (Luye Pharma)
- For treating schizophrenia in adults and for treating schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.
- Zunveyl (Alpha Cognition)
- For the treatment of mild-to-moderate Alzheimer’s disease.
- Xembify (Grifols)Expanded Indication
- For treatment-naïve patients with primary humoral immunodeficiencies (PI).
- Leqselvi (Sun Pharma)
- For the treatment of adults with severe alopecia areata.
- Xeomin (Merz Aesthetics)New Indication
- For the simultaneous treatment of upper facial lines – forehead lines, frown lines and crow’s feet.
- Femlyv (Millicent Puerto Rico)
- For the prevention of pregnancy.
- Epysqli (Samsung Bioepis)Biosimilar
- For the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.
- Zituvimet XR (Zydus Lifesciences)
- An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Voquezna (Phathom Pharmaceuticals)New Indication
- For the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults.
- Zoryve (Arcutis Biotherapeutics)Expanded Indication
- For the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.
- Vabysmo (Genentech)New Formulation
- For use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).
- Kisunla (Eli Lilly)
- For adults with early symptomatic Alzheimer’s disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.
- Pyzchiva (Sandoz)Biosimilar to Stelara
- Multiple indications as a biosimilar to Stelara.
- Ahzantive (Formycon)Biosimilar to Eylea
- Multiple indications as a biosimilar to Eylea
Sign up for alerts and stay informed on the latest published guidelines, FDA decisions, and more!
Copyright © 2024 Guideline Central, All Rights Reserved.